Combined repetitive transcranial magnetic stimulation and mirror therapy for upper limb rehabilitation in stroke survivors: A systematic review and meta-analysis.

Neurol SciSep 29, 2026 (epub)
Clinical ResearchPhysical Medicine & RehabilitationOpen access

Anas R Alashram

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of combined repetitive transcranial magnetic stimulation (rTMS) and mirror therapy (MT) on upper limb rehabilitation in stroke survivors. Analyzing data from seven randomized controlled trials involving 402 participants, significant improvements were found in the Fugl-Meyer Assessment for Upper Extremity (SMD = 0.92) and the Box and Block Test (SMD = 1.09).

Key findings

  • Significant improvement in Fugl-Meyer Assessment for Upper Extremity (SMD = 0.92, p = 0.0002).
  • Significant improvement in Box and Block Test (SMD = 1.09, p = 0.0003).
  • Other outcomes showed improvements in pinch grip, hand grip, and functional performance.

Why it matters

The findings suggest that combining rTMS and MT may enhance upper limb function in stroke survivors, addressing a common and impactful rehabilitation challenge. Understanding these effects can inform treatment strategies in stroke rehabilitation.

Source

PubMed · PMID 42809058Free full text on PubMed Central

Published in Neurol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.